Complicated Skin and Skin Structure Infections Drugs Global Market Report 2024

The global complicated skin and skin structure infections drugs market has grown rapidly in recent years. It will grow from $8.55 billion in 2023 to $9.51 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to infectious disease prevalence, increase in hospital-acquired infections, prevalence of complicated skin and skin structure infections, growing demand for effective treatment options, rising disposable incomes.

The global complicated skin and skin structure infections drugs market is expected to see strong growth in the next few years. It will grow to $13.78 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to increasing healthcare expenditure, increasing investment in r&d activities, rising demand for novel antibiotics, increasing incidence of antibiotic-resistant infections, growing demand for personalized medicine. Major trends in the forecast period include advancements in wound care products, targeted antibiotics, digital health monitoring, natural and alternative remedies, global collaborations.

The increasing prevalence of skin diseases is poised to drive the growth of the complicated skin and skin structure infections (cSSSI) drugs market in the foreseeable future. Skin diseases encompass a range of medical conditions that impact the skin's appearance, structure, and functionality, including conditions affecting the skin, hair, nails, and associated tissues. Various antibiotic drugs play a crucial role in combating drug-resistant bacteria associated with cSSSI. Consequently, the upsurge in skin disease cases may lead to the approval of new drugs for cSSSI, foster greater awareness, and encourage early diagnosis of complicated skin and skin structure infections. For instance, data from the American Academy of Dermatology Association in April 2022 indicated that approximately 9,500 individuals in the United States receive a skin cancer diagnosis daily. Additionally, the Centers for Disease Control and Prevention (CDC) reported in March 2023 that the total number of deaths attributed to fungal infections increased from 5,922 in 2020 to 7,199 in 2021. Thus, the growing prevalence of skin diseases acts as a driving force behind the expansion of the complicated skin and skin structure infections drugs market.

The upward trend in healthcare expenditure is poised to be a significant driver of the complicated skin and skin structure infections (cSSSI) drugs market's growth in the foreseeable future. Healthcare expenditure encompasses the total financial outlay on healthcare services, as well as related goods and activities, within a specific healthcare system or economy during a defined period. Escalating healthcare costs are of particular importance in the realm of medications for complex skin and skin structure infections (cSSSI). Not only does increased healthcare spending facilitate greater access to healthcare services, but it also provides crucial funding for research, development, and the distribution of cSSSI drugs. For instance, as of May 2023, a report from the UK's Office for National Statistics revealed that healthcare spending in the United Kingdom experienced a 9.4% increase in nominal terms and a 9.7% increase in real terms between 2020 and 2021. In 2021, the total healthcare expenditure in the UK amounted to $367.25 billion (£280.7 billion), with pharmaceutical expenditure reaching $51.84 billion (£39.6 billion) during the same year. Spending on preventive care in 2021 stood at $45.93 billion (£35.1 billion), more than doubling from 2020. Therefore, the surge in healthcare spending plays a pivotal role in driving the expansion of the complicated skin and skin structure infections drugs market.

The emergence of antibiotic-resistant bacteria presents a noteworthy challenge and has the potential to impede the growth of the market during the projected period. Antibiotic-resistant bacteria denote strains of bacteria that have evolved to resist one or more antibiotics, rendering them challenging to treat. Such a development can curtail the efficacy of existing antibiotics and instigate a heightened demand for novel antibiotic solutions. A case in point is methicillin-resistant Staphylococcus aureus (MRSA), a bacterial strain demonstrating resistance to a multitude of antibiotics and capable of causing complicated skin and skin structure infections. In response, new antibiotics like oritavancin have been developed for the treatment of complicated skin and skin structure infections. Consequently, the emergence of antibiotic-resistant bacteria represents an obstacle to the unhindered expansion of the complicated skin and skin structure infections drugs market.

To maintain their competitive positions in the complicated skin and skin structure infections drugs market, major companies are committed to developing cutting-edge products. As a case in point, in January 2022, Paladin Labs Inc., a Canadian pharmaceutical company and a subsidiary of Endo International PLC, introduced Xydalba (dalbavancin for injection) in the Canadian market. Xydalba is an intravenous treatment designed for both adults and children aged three months and above, addressing acute bacterial skin and skin structure infections (ABSSSI). This second-generation semi-synthetic lipoglycopeptide antibiotic functions by disrupting the formation of bacterial cell walls, effectively eradicating the bacteria. It demonstrates effectiveness against numerous gram-positive bacteria, including the formidable methicillin-resistant Staphylococcus aureus (MRSA). ABSSSI, denoting Acute Bacterial Skin and Skin Structure Infections, forms a specific subset of complicated skin and skin structure infections (cSSSI).

In March 2022, Cumberland Pharmaceuticals, a pharmaceutical firm based in the United States, joined forces with Tabuk Pharmaceuticals Manufacturing Company to create an innovative antibiotic with life-saving potential for the Middle East. This partnership marked the official launch of Cumberland's Vibativ (telavancin) injection in the Middle East. Vibativ stands as an advanced antibiotic developed to address complicated skin and skin structure infections (cSSIs) attributed to susceptible isolates of gram-positive bacteria. The collaboration entails the exclusive authorization for Tabuk to register and promote the product to patients across Saudi Arabia, Jordan, and potentially other nations in the Middle East. Tabuk Pharmaceuticals Manufacturing Company is a pharmaceutical enterprise headquartered in Saudi Arabia, specializing in the provision of pharmaceutical products within the Middle East and North America.

Major players in the complicated skin and skin structure infections drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Merck & Co. Inc., AstraZeneca PLC, Abbott Laboratories, Sanofi SA, GlaxoSmithKline PLC, Eli Lilly and Company, Cipla Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Fresenius Kabi, Macleods Pharmaceuticals, Sun Pharmaceutical Industries Limited, Dr Reddy's Laboratories Ltd, Lupin Pharmaceuticals, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, LEO Pharma, Wockhardt, Paratek Pharmaceuticals, Basilea Pharmaceutica AG, Melinta Therapeutics Inc., Nabriva Therapeutics AG, MerLion Pharmaceuticals GmbH.

Asia-Pacific was the largest region in the complicated skin and skin structure infections drugs market in 2023. The regions covered in complicated skin and skin structure infections drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the complicated skin and skin structure infections drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary active ingredients found in drugs for complicated skin and skin structure infections include delafloxacin, vancomycin, ceftaroline, fosamil, linezolid, and others. Delafloxacin, for instance, belongs to the fluoroquinolone antibiotic class, and it is employed for the treatment of skin and skin structure infections caused by specific bacteria. These drugs can be administered through various routes, including oral, topical, and parenteral, and they are utilized by a range of end users, such as hospitals, homecare services, specialty clinics, and others.

This report provides complicated skin and skin structure infections drugs market statistics, including complicated skin and skin structure infections drugs industry global market size, regional shares, competitors with a complicated skin and skin structure infections drugs market share, detailed complicated skin and skin structure infections drugs market segments, market trends and opportunities and any further data you may need to thrive in the complicated skin and skin structure infections drugs industry. This complicated skin and skin structure infections drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The complicated skin and skin structure infections drugs market consists of sales of pain medications, immunosuppressive medications, antiseptics and wound dressings. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.